Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 252

1.

Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10843-8. Epub 2002 Jul 26.

2.

Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain.

Martin-Rehrmann MD, Hoe HS, Capuani EM, Rebeck GW.

Neurotox Res. 2005;7(3):231-42.

PMID:
15897157
3.

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM.

Neuron. 2004 Jan 22;41(2):193-202.

4.

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2892-7.

5.
6.

Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ.

Miners JS, Clarke P, Love S.

Brain Pathol. 2017 May;27(3):305-313. doi: 10.1111/bpa.12392. Epub 2016 Jul 8.

PMID:
27248362
7.

Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42).

Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E.

J Neurosci Res. 2001 Nov 15;66(4):573-82.

PMID:
11746377
8.

Cat and mouse.

Cole GM, Frautschy SA.

Neuron. 2006 Sep 21;51(6):671-2.

9.

Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease.

Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L.

Neuron. 2006 Sep 21;51(6):703-14.

10.

Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's.

Borbon IA, Erickson RP.

J Appl Genet. 2011 May;52(2):213-8. doi: 10.1007/s13353-010-0021-1. Epub 2010 Dec 18.

PMID:
21170692
11.

Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Bussière T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, Buttini M.

Am J Pathol. 2004 Sep;165(3):987-95.

12.

Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.

van Groen T, Kiliaan AJ, Kadish I.

Neurobiol Dis. 2006 Sep;23(3):653-62. Epub 2006 Jul 10.

PMID:
16829076
13.

Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease.

Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, Maniar K, Dolios G, Wang R, Hof PR, Pasinetti GM.

FASEB J. 2005 Apr;19(6):659-61. Epub 2005 Jan 13.

PMID:
15650008
14.

Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice.

Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM.

J Neurosci. 2003 Aug 27;23(21):7889-96.

15.

Limited expression of heparan sulphate proteoglycans associated with Aβ deposits in the APPswe/PS1dE9 mouse model for Alzheimer's disease.

Timmer NM, Herbert MK, Kleinovink JW, Kiliaan AJ, De Waal RM, Verbeek MM.

Neuropathol Appl Neurobiol. 2010 Oct;36(6):478-86. doi: 10.1111/j.1365-2990.2010.01091.x.

PMID:
20831743
16.

Alzheimer's disease and amyloid: culprit or coincidence?

Skaper SD.

Int Rev Neurobiol. 2012;102:277-316. doi: 10.1016/B978-0-12-386986-9.00011-9. Review.

PMID:
22748834
17.

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.

Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML.

Neuron. 2012 Dec 6;76(5):908-20. doi: 10.1016/j.neuron.2012.10.029.

18.

Suppression of Alzheimer's disease-related phenotypes by expression of heat shock protein 70 in mice.

Hoshino T, Murao N, Namba T, Takehara M, Adachi H, Katsuno M, Sobue G, Matsushima T, Suzuki T, Mizushima T.

J Neurosci. 2011 Apr 6;31(14):5225-34. doi: 10.1523/JNEUROSCI.5478-10.2011.

19.

PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures.

Brendza RP, O'Brien C, Simmons K, McKeel DW, Bales KR, Paul SM, Olney JW, Sanes JR, Holtzman DM.

J Comp Neurol. 2003 Feb 17;456(4):375-83.

PMID:
12532409
20.

The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice.

Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM.

J Biol Chem. 2005 Jul 8;280(27):25754-9. Epub 2005 May 11.

Supplemental Content

Support Center